Adaptimmune Strengthens Management Team with Key Executive Hires
Adaptimmune announced the appointments of Dr. Rafael Amado as Chief Medical Officer and Adrian (Ad) Rawcliffe as Chief Financial Officer, with effect of March 16, 2015.
Dr. Amado will lead Adaptimmune's clinical strategy and assume responsibility for the company's clinical trials across the US and Europe under its strategic collaboration with GlaxoSmithKline (GSK). He will also lead the development of the company's pipeline of wholly-owned research programs. Prior to joining Adaptimmune, Dr. Amado served as Senior Vice President and Head of Oncology R&D at GSK. He joined GSK in 2008 as Vice President of Clinical Development, and served in positions of increasing responsibility, including Senior Vice President and Head of Oncology Clinical Development. Before his time at GSK, Dr. Amado was Executive Director of Therapeutic Oncology at Amgen. He trained as a Hematologist/Oncologist at the University of California, Los Angeles.
Adrian Rawcliffe will lead Adaptimmune's financial management and operations functions including compliance and risk management. He joins from GSK where he was Senior Vice President, Finance of its North American Pharmaceuticals business. Prior to this, Rawcliffe held a variety of senior finance and business development roles at GSK, including Senior Vice President Worldwide Business Development and R&D Finance, and Managing Partner and President of SR One, GSK's venture-capital business. He joined GSK in 1998 and holds a BSc degree in Natural Sciences from the University of Durham, UK. He qualified as a Chartered Accountant with Coopers & Lybrand.
most read
GSK to Invest $800 Million in US Manufacturing Facility
British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.
New Deal to Boost Competitiveness
The EU Green Deal has hurt Europe's industry. The Clean Industrial Deal aims to improve this, but a change of mindset at the Commission is needed.
And the Winners are: Cynio, EnaDyne and Green Li-ion
The CHEManager Innovation Pitch, the start-up promotion initiative of CHEManager and CHEManager International, has given more than 100 start-ups from over 15 countries the opportunity to present their innovative ideas, products and technologies to a broad target group since its launch in 2019.
Future Prospects in Green Chemistry
The Discourse on Green Chemistry Interactive Pitch Competition, held on November 5, 2024, at Wiley's Berlin office as part of Berlin Science Week, showcased a range of innovative projects aimed at addressing critical environmental challenges.
CEFIC President Calls for EU Action on Chemicals Rescue Plan
Europe's chemical industry is in crisis, warns the European Chemical Industry Council (CEFIC) President Ilham Kadri, urging EU leaders to act on a 10-point rescue plan to prevent further shutdowns and loss of investments.